L.a.n.c.e. Chemosensitivity testing at the highest level· Laboratory for Applied Neoplasia Research and Cytostatics Evaluation

Literatur Zum ATP-TCA liegen zahlreiche wissenschaftliche Studienergebnisse vor. Vor allem die klinischen Studien belegen die hohe prädiktive Aussagefähigkeit des Verfahrens, das sich nicht nur bei der individuellen Therapieplanung, sondern auch in der Entwicklung innovativer Therapieregime bereits hervorragend bewährt hat.

International Literature
A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer.
In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group.
Feasibility of chemosensitivity testing in soft tissue sarcomas.
Prediction of individual response to chemotherapy in patients with acute myeloid leukaemia using the chemosensitivity index Ci.
In vitro chemosensitivity to gemcitabine, oxaliplatin and zoledronic acid predicts treatment response in metastatic gastric cancer.
ATP chemosensitivity testing in ovarian and breast cancer: early clinical trials.
Chemosensitivity testing in malignant melanoma.
Chemosensitivity testing in gynecologic oncology–dream or reality?

Cree, Ian A. a; Kurbacher, Christian M. e; Lamont, Alan b; Hindley, Andrew C. c; Love, Sharon d; for the TCA Ovarian Cancer Trial Group
.
Anti-Cancer Drugs. 18(9):1093-1101, October 2007.

The primary aim of this randomized trial was to determine response rate and progression-free survival following chemotherapy in patients with platinum-resistant recurrent ovarian cancer, who had been treated according to an ATP-based tumour chemosensitivity assay in comparison with physician's choice.
A total of 180 patients were randomized to assay-directed therapy (n=94) or physician's-choice chemotherapy (n=86). Median follow-up at analysis was 18 months. Response was assessable in 147 patients: 31.5% achieved a partial or complete response in the physician's-choice group compared with 40.5% in the assay-directed group (26 versus 31% by intention-to-treat analysis respectively).

Intention-to-treat analysis showed a median progression-free survival of 93 days in the physician's-choice group and 104 days in the assay-directed group (hazard ratio 0.8, 95% confidence interval 0.59-1.10, not significant). No difference was seen in overall survival between the groups, although 12/39 (41%) of patients who crossed over from the physician's-choice arm obtained a response. Increased use of combination therapy was seen in the physician's-choice arm during the study as a result of the observed effects of assay-directed therapy in patients. Patients entering the physician's-choice arm of the study during the first year did significantly worse than those who entered in the subsequent years (hazard ratio 0.44, 95% confidence interval 0.2-0.9, P<0.03).

This small randomized clinical trial has documented a trend towards improved response and progression-free survival for assay-directed treatment. Chemosensitivity testing might provide useful information in some patients with ovarian cancer, although a larger trial is required to confirm this.
The ATP-based tumour chemosensitivity assay remains an investigational method in this condition.